| Bioactivity | Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection[1][2]. |
| Invitro | Suvizumab 对 G314E 突变的假型病毒表现出高度抗性[3]。 |
| In Vivo | Suvizumab (15、30 和 45 mg/kg；静脉注射；单剂量) 在感染 SHIV C2/1 的食蟹猴中，以剂量依赖性方式弱化了病毒攻击和血浆病毒血症，增加了 CD4+ T 细胞数[2]。Suvizumab (45 mg/kg；静脉注射；一周一次持续 2 个月) 在感染猿猴/人类免疫缺陷病毒-C2/1 的雄性食蟹猴中，降低了淋巴组织中 CD4 T 细胞的损失[4]。 |
| Name | Suvizumab |
| CAS | 914257-21-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Matsushita S, et al. Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS. 2015 Feb 20;29(4):453-62. [2]. Eda Y, et al. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J Virol. 2006 Jun;80(11):5563-70. [3]. Yoshimura K, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS. 2006 Oct 24;20(16):2065-73. [4]. Murakami T, et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS. 2009 Jul 31;23(12):1485-94. |